# A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy

> **NCT02368652** · PHASE3 · COMPLETED · sponsor: **HK inno.N Corporation** · enrollment: 181 (actual)

## Conditions studied

- Essential Hypertension

## Interventions

- **DRUG:** Candesartan cilexetil 16mg
- **DRUG:** Amlodipine 10mg, Candesartan cilexetil 16mg

## Key facts

- **NCT ID:** NCT02368652
- **Lead sponsor:** HK inno.N Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-11
- **Final completion:** 2015-11
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02368652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02368652, "A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02368652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*